GBIM:OTCMKTS
GlobeImmune Inc
0,00010 $
0,00%
(0,00) 1D
29. sep., 15:48:52 GMT -4 · USD
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za GBIM …
Tržna kapitalizacija
580,00
Povprečni promet
1,74 tis.
Promet
0,00
52-tedenski najvišji tečaj
0,04 $
52-tedenski najnižji tečaj
0,00 $
Št. izdanih delnic
5,75 mio.
Št. zaposlenih
22
Tržna kapitalizacija
580,00
Povprečni promet
1,74 tis.
Promet
0,00
52-tedenski najvišji tečaj
0,04 $
52-tedenski najnižji tečaj
0,00 $
Št. izdanih delnic
5,75 mio.
Št. zaposlenih
22
Novice
Iz spletnih virov in novičarskih partnerjev
Foreign Policy Journal
·
pred 12 minutami
Microsoft (NASDAQ: MSFT) Unveils Maia 300 AI Chip To Challenge Nvidia (NASDAQ: NVDA) On Cost
GlobeNewswire
·
pred 53 minutami
AZIO AI Holdings Inc. (NASDAQ: AZIO) Building Solution to
CNN
·
pred 2 urama
Global tech selloff deepens as enthusiasm for AI stocks wobbles
Seeking Alpha
·
pred 1 uro
The Outlook For S&P 500 Dividends In October 2026 (undefined:SPX)
Profil
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Vizitka: GlobeImmune Inc
Generalni direktor-
Št. zaposlenih22
Ustanovljeno1. jan. 1995
SedežLouisville, Kolorado, Združene države Amerike
Sektor-
Spletno mestoglobeimmune.com